Diversity Organization of the Year
Top Doctors 2020
Glaucoma Treatment
Tyrogenex Studies Oral Treatment for Wet AMD

Tyrogenex studies oral treatment for wet AMD. Tyrogenex (West Palm Beach, FL) said it has initiated a phase 2 clinical trial for its X-82 anti-VEGF/anti-PDGF oral therapy for patients previously treated for wet AMD. The 132-patient, 52-week “APEX” study, to be conducted at 20 US and five UK sites, has dual endpoints of improved visual acuity and a reduction in anti-VEGF injections.

A recently completed phase 1 trial of the tyrosine kinase inhibitor X-82 showed that 24 of the 27 previously treated subjects who completed the 24-week study needed no anti-VEGF rescue during the study period. The majority maintained or improved their baseline visual acuity.

Source/Retinal Physician